Navigation Links
Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
Date:3/20/2008

cancer, and more than 52,000 people are expected to die from it in the U.S. this year.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Lookin
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
6. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
7. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
8. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
9. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Clementia Pharmaceuticals, Inc.  announced ... has granted Orphan Medicinal Product Designation for ... the treatment of fibrodysplasia ossificans progressiva (FOP). ... disease characterized by painful, recurrent episodes of ... bone formation. This process, known as heterotopic ...
(Date:11/21/2014)... 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced ... will be presenting at the 26 th Annual Piper ... New York . The formal presentation is ... In addition, Mr. Krakauer and Jorgen B. Hansen , ... during the day. An audio webcast will ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3
... 17, 2012  Eisai announced today that 15 abstracts highlighting new ... Annual Meeting of the American Society of Clinical Oncology (ASCO), ... 2012. These studies highlight Eisai,s current product ... and their families affected by cancer. "Our ...
... Janssen Pharmaceuticals, Inc. today announced the results ... ER (tapentadol) extended-release tablets were significantly more effective ... with chronic moderate to severe, painful diabetic peripheral ... at the 31st Annual Scientific Meeting of the ...
Cached Medicine Technology:Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 2Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 3Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 4Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 5Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 6Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 7Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 8Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 2Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 3Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 4Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 5Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 6Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 7Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 8Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 9Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 10Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 11Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN) 12
(Date:11/22/2014)... November 23, 2014 Today, Dylan Queen, ... new collection of wedding dresses; the business offers a ... related accessories for ladies worldwide, allowing them to create ... of the company, this new collection of chic wedding ... Moreover, they are offered at discounted rates now. Dylan ...
(Date:11/22/2014)... 22, 2014 Discount-Dress.com is an ... the firm is to increase the company’s online market share ... new selection of bridesmaid dresses and announced a bridesmaid dress ... valid until Dec. 30, 2014. All the dresses from this ... , In fact, Discount-Dress.com is very good at manufacturing ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 "My friend ... pain caused by the machine," said an inventor from ... had to go back a second time because the ... idea." , She developed the patent-pending MAMO EASY to ... cancer. The design saves the patient from the pain ...
(Date:11/22/2014)... The wide variety and complexity of foods served at ... food allergies, an expert warns. "Every person is ... allergies that it can be really difficult to avoid ... of allergy and clinical immunology at Wake Forest Baptist ... "If you know you have food allergies, caution should ...
(Date:11/22/2014)... This month has been a historical time for Angeldress.co.uk, ... positive reviews from some renowned review websites. Recently, the company ... a new selection of wonderful sexy wedding dresses to its ... shipping and up to an 80% discount on any order ... the most suitable dress at Angeldress.co.uk, which has garnered a ...
Breaking Medicine News(10 mins):Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2
... metalloproteinase 1 and vitamin D synthesis may determine the ... ,The researchers analysed genetic variations in 312 people, just ... replacement in the 10 years following surgery. ... 'aseptic loosening,' which describes a condition in which the ...
... March 14 (IANS) India Wednesday launched a major initiative ... NGO// in Tamil Nadu planning a usage study in ... with the Hindustan Latex Ltd and the National Aids ... to provide female condoms at just Rs.3 to NGOs ...
... move could force pharmaceutical companies into a reformulation drive ... flu products// that do not contain the restricted ingredients. ... letter seeking opinion on the proposed restrictions, which would ... reduction in pack size by the end of 2007. ...
... pressure could certainly be an indicator of one’s happiness. Researchers ... between a nation's overall happiness and its citizens' blood pressure ... people from across the European countries. ,These people were asked ... hypertension (high blood pressure) and so on. ,While ...
... Brasilia – Svelte models have lent their charm in the many ... enviable trend//, a recent survey has painted a different picture of ... thought to be and the men drink far too much. Nearly ... over weight category, the survey revealed. ,Sao Paulo, the ...
... discovered a new type of cells, which they say appear ... ,The medical team led by Jian-Xin Gao at Ohio ... or pCSCs, that can either remain benign or become malignant, ... cells are very complex. They have properties of normal and ...
Cached Medicine News:Health News:India to Market Female Condoms 2Health News:UK to Pull Pseudoephedrine 2Health News:UK to Pull Pseudoephedrine 3
... reliable strength for temporary wound support. ... compliant and stretchable support material is ... is not required. Predictable absorption. Polyglactin ... inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... is designed for the repair of abdominal ... that has two distinct sides. One ... a layer of sodium hyaluronate and carboxymethylcellulose ... This coated side is bioresorbable, providing a ...
... Human explant studies have confirmed ... for maximum clinical performance in hernia ... Atriums thinner and less dense hernia ... less rigid repair. Since 1994, when ...
Medicine Products: